Home / Stock ratings / Healthcare Stocks / ABBV
Stock rating · Pharmaceutical Preparations
AbbVie Inc. (ABBV) Stock Rating & Analysis
As of November 20, 2026, MELANY rates AbbVie Inc. 63 out of 100 (Runner!). Its highest factor score is business quality at 81, and its lowest is macro fit at 50.
ABBV · composite score
About AbbVie Inc.
AbbVie is a pharmaceutical firm with strong exposure to immunology (Humira, Skyrizi, and Rinvoq) and oncology (Imbruvica and Venclexta), spun off from Abbott in early 2013. Its 2020 acquisition of Allergan added products and drugs in aesthetics including Botox, and its 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) further supplement its portfolio.
Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How ABBV's rating has moved
- +5Past three weeks, since Oct 30: now flagged Runner!, a separate short-term momentum flag rather than a step up or down, with its score rose 5 points to 63.
Weekly points: Oct 30: 58 · Nov 20: 63 (this page).
From MELANY's own dated rating record. A tier change is reported as a move between named tiers; the score carries the direction.
Why ABBV scores 63/100
ABBV's 8 factor scores run from 50 to 81, and 3 of them sit above its composite of 63. Here is how ABBV breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 17.6x, earnings growth accelerating
- PEG ratio 0.57 (< 1 = undervalued)
Margins, returns on capital, and balance-sheet strength.
- Gross margin 74%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ABBV compares
As of November 20, 2026, AbbVie Inc. is tied for 8th of 20 in Healthcare Stocks, where the average score is 62.
Key risks for ABBV
- Performance partly driven by Healthcare sector, rotation away from this theme would hurt
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
AbbVie Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds ABBV's momentum and catalyst factors above.
ABBV trade plan (Pro)
MELANY has a full position plan for AbbVie Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates ABBV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. AbbVie Inc.'s 63/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ABBV
Is AbbVie Inc. (ABBV) a buy?
As of 2026-11-20, MELANY rated AbbVie Inc. Runner! with a composite score of 63/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
How has ABBV's rating changed recently?
As of 2026-11-20, MELANY scores ABBV 63/100 (Runner!); 3 weeks earlier (Oct 30) it was 58. These points come from MELANY's own dated rating record.
How does ABBV rank against similar companies?
As of November 20, 2026, AbbVie Inc. is tied for 8th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).
Should I buy AbbVie Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates AbbVie Inc. (ABBV) Runner! with a composite of 63/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ABBV stock price forecast?
MELANY does not publish price targets or forecasts for ABBV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 63/100 across eight factors for AbbVie Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for ABBV as of 2026-11-20: its analyst sentiment factor is 68/100, and its price momentum factor is 72/100.
Is ABBV stock overvalued or undervalued?
MELANY's valuation factor currently reads 53/100 for AbbVie Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ABBV's read.
What price should I buy ABBV at?
Rather than chasing the current price, MELANY computes a smart entry zone for ABBV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying ABBV stock?
The top risks MELANY currently flags for AbbVie Inc.: Performance partly driven by Healthcare sector, rotation away from this theme would hurt; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is AbbVie Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 81/100 for AbbVie Inc., and earnings track record, at 57/100. The 63/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ABBV stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 72/100 for ABBV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ABBV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores ABBV as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ABBV included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.